tert-butyl 4-picolinoylpiperidine-1-carboxylate | 416852-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-picolinoylpiperidine-1-carboxylate
• 英文别名: 4-(Pyridine-2-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(pyridine-2-carbonyl)piperidine-1-carboxylate
• CAS: 416852-19-2
• 化学式: C₁₆H₂₂N₂O₃
• 分子量: 290.362
• InChiKey: BYZFMBNHJIKXTM-UHFFFAOYSA-N

物化性质

• 沸点：
  407.4±35.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-picolinoylpiperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 piperidin-4-yl(pyridin-2-yl)methanone
  参考文献：
  名称：

  [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE

  摘要：

  本发明提供了式(I)的化合物，其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物，以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途，包括但不限于癌症。

  公开号：

  WO2013012723A1
• 作为产物：
  描述：

  1-Boc-4-[甲氧基(甲基)氨基甲酰]哌嗪 在 2-pyridylmagnesium halide 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl 4-picolinoylpiperidine-1-carboxylate
  参考文献：
  名称：

  Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres

  摘要：

  This Letter describes the development and SAR of a novel series of GlyT1 inhibitors derived from a scaffold hopping approach, in lieu of an HTS campaign, which provided intellectual property position. Members within this new [3.3.0]-based series displayed excellent GlyT1 potency, selectivity, free fraction, and modest CNS penetration. Moreover, enantioselective GlyT1 inhibition was observed, within this novel series and a number of other piperidine bioisosteric cores. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.011

文献信息

• Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20070010513A1

  公开（公告）日：2007-01-11

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R 1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐，其中： M1和M3为CH或N； M2为CH、CF或N； Y为—C(═O)—、—C(═S)—、—(CH2)q—、—C(═NOR7)—或—SO1-2—；Z为键或可选择地取代的烷基或烯基； R1为H、烷基、烯基，或可选择地取代的环烷基、芳基、杂芳基、杂环烷基或下式的基团： 其中环A为单杂芳基环； R1为可选择地取代的烷基、烯基、芳基、杂芳基、环烷基或杂环烷基；其余变量如规范中所定义；使用这些化合物，单独或与其他药剂结合，治疗过敏引起的气道反应、充血、肥胖、代谢综合征、非酒精性脂肪肝病、肝脂肪变性、非酒精性脂肪性肝炎、肝硬化、肝细胞癌或认知缺陷症状的组合物和治疗方法。
• [EN] OXIME COMPOUNDS USEFUL AS T CELL ACTIVATORS<br/>[FR] COMPOSÉS OXIME UTILES COMME ACTIVATEURS DE LYMPHOCYTES T
  申请人：GOSSAMER BIO SERVICES INC

  公开号：WO2021258010A1

  公开（公告）日：2021-12-23

  Disclosed herein are oxime compounds having the structure of Formula (I):or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein R1, R2, R3, a, L, X, and Y are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  本文披露了具有Formula (I)结构的肟化合物：或其药用可接受的盐、溶剂化合物、水合物、异构体、互变异构体、拉氏体、或同位素，其中R1、R2、R3、a、L、X和Y如本文所定义。还提供了包括它们的药物组合物、制备它们的方法以及用途，用于治疗或预防疾病、紊乱和状况。这些化合物是二酰甘油激酶α(DGKα)和二酰甘油激酶ζ(DGKζ)的抑制剂，并且在治疗与DGKα和/或DGKζ活性相关的疾病、紊乱和状况方面是有用的。特别地，这些化合物对于治疗病毒感染和增生性疾病，如癌症，是有用的。
• Visible Light-Driven Decarboxylative Alkylation of Aldehydes via Electron Donor–Acceptor Complexes of Active Esters
  作者：Fang-Yuan Nie、Yi-Ping Cai、Qin-Hua Song

  DOI：10.1021/acs.joc.1c02586

  日期：2022.1.21

  this paper, we have developed photocatalyst-free and visible light-driven decarboxylative alkylation of pyridinaldehydes. The photochemical reactions are initiated via photoinduced single electron transfer from triethylamine to N-hydroxyphthalimide esters in electron donor–acceptor complexes. This photochemical method can achieve to translate 15 pyridinaldehydes and 11 2-quinolinaldehydes to the corresponding

  有一些从广泛使用的醛到相应的酮的合成方法，但是它们涉及与格氏试剂或过渡金属催化剂的多步反应。在本文中，我们开发了无光催化剂和可见光驱动的吡啶醛脱羧烷基化。光化学反应是通过在电子供体-受体复合物中从三乙胺到N-羟基邻苯二甲酰亚胺酯的光诱导单电子转移引发的。这种光化学方法可以实现将15个吡啶醛和11个2-喹啉醛转化为相应的酮。此外，该策略还可以实现另外两种转化，二硫烷转化为芳基硫化物，苯乙烯砜转化为烷基取代的烯烃。
• 10th international symposium on the synthesis and applications of isotopes and isotopically labelled compounds-synthesis of compounds labelled with long-lived isotopes Session 17, Thursday, June 18, 2009
  作者：Karl Cable、John Easter

  DOI：10.1002/jlcr.1773

  日期：——

  This session is a continuation of Session 1. A number of methods detailing the synthesis of tritiated compounds as well as a discussion on the handling of tritium on a multi-Curie scale are presented. In addition, the descriptions of a number of preparations of individual isotopically labelled compounds are detailed. Copyright © 2010 John Wiley & Sons, Ltd.

  本次会议是第1次会议的延续。介绍了一些合成氚化合物的方法，并讨论了在多居里规模下处理氚的相关事宜。此外，还详细描述了一些个体同位素标记化合物的制备方法。版权 © 2010 John Wiley & Sons, Ltd.
• Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes
  作者：Yoshihiro Banno、Shigekazu Sasaki、Makoto Kamata、Jun Kunitomo、Yasufumi Miyamoto、Hidenori Abe、Naohiro Taya、Satoru Oi、Masanori Watanabe、Tomoko Urushibara、Masatoshi Hazama、Shin-ichi Niwa、Saku Miyamoto、Akira Horinouchi、Ken-ichi Kuroshima、Nobuyuki Amano、Shin-ichi Matsumoto、Shinichiro Matsunaga

  DOI：10.1016/j.bmc.2017.09.031

  日期：2017.11

  The discovery of a novel series of β-methyltryptophan (β MeTrp) derivatives as selective and orally active non-peptide somatostatin receptor 2 (SSTR2) agonists for the treatment of Type 2 diabetes is described. In our previous research, Compound A, β-MeTrp derivative with highly potent and selective SSTR2 agonistic activity IC50 (SSTR2/SSTR5) = 0.3/>100 (nM), was identified as a drug candidate for

  描述了发现一系列新型的β-甲基色氨酸（βMeTrp）衍生物作为选择性和口服活性非肽生长抑素受体2（SSTR2）激动剂，用于治疗2型糖尿病。在我们之前的研究中，化合物A，β-MeTrp衍生物具有强效的选择性SSTR2激动活性IC 50（SSTR2 / SSTR5）= 0.3 /> 100（nM）被确定为治疗2型糖尿病的候选药物，该药物可显着降低Wistar脂肪大鼠口服中的血浆葡萄糖水平。然而，由于在大鼠的毒理学研究中观察到AUC和磷脂病（PLsis）的严重增加，因此根据在HepG2中磷脂积累的基础上评估的体外PLsis潜力，对后续化合物进行了研究以避免PLsis的风险暴露于化合物的细胞。 已经发现将羰基引入化合物A和B的哌啶和哌嗪或苯胺部分上显着降低了体外PLsis电位。化合物的进一步修饰及其评估导致发现具有较低体外PLsis电位的化合物3k，其在SD大鼠中表现出低血糖诱导的胰高血糖素分泌降低的作用（ED